TY - JOUR
T1 - Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine
AU - Durbin, Anna P.
AU - Kirkpatrick, Beth D.
AU - Pierce, Kristen K.
AU - Schmidt, Alexander C.
AU - Whitehead, Stephen S.
N1 - Funding Information:
This vaccine development project was supported by the NIAID Division of Intramural Research at the NIH . Oversight of the clinical trials was provided by the Laboratory of Infectious Diseases with the NIAID Division of Clinical Research serving as the IND sponsor.
PY - 2011/9/23
Y1 - 2011/9/23
N2 - The Laboratory of Infectious Diseases at the National Institute of Allergy and Infectious Diseases, National Institutes of Health has been engaged in an effort to develop a safe, efficacious, and affordable live attenuated tetravalent dengue vaccine (LATV) for more than ten years. Numerous recombinant monovalent DENV vaccine candidates have been evaluated in the SCID-HuH-7 mouse and in rhesus macaques to identify those candidates with a suitable attenuation phenotype. In addition, the ability of these candidates to infect and disseminate in Aedes mosquitoes had also been determined. Those candidates that were suitably attenuated in SCID-HuH-7 mice, rhesus macaques, and mosquitoes were selected for further evaluation in humans. This review will describe the generation of multiple candidate vaccines directed against each DENV serotype, the preclinical and clinical evaluation of these candidates, and the process of selecting suitable candidates for inclusion in a LATV dengue vaccine.
AB - The Laboratory of Infectious Diseases at the National Institute of Allergy and Infectious Diseases, National Institutes of Health has been engaged in an effort to develop a safe, efficacious, and affordable live attenuated tetravalent dengue vaccine (LATV) for more than ten years. Numerous recombinant monovalent DENV vaccine candidates have been evaluated in the SCID-HuH-7 mouse and in rhesus macaques to identify those candidates with a suitable attenuation phenotype. In addition, the ability of these candidates to infect and disseminate in Aedes mosquitoes had also been determined. Those candidates that were suitably attenuated in SCID-HuH-7 mice, rhesus macaques, and mosquitoes were selected for further evaluation in humans. This review will describe the generation of multiple candidate vaccines directed against each DENV serotype, the preclinical and clinical evaluation of these candidates, and the process of selecting suitable candidates for inclusion in a LATV dengue vaccine.
KW - Clinical trial
KW - Dengue
KW - Vaccine development
UR - http://www.scopus.com/inward/record.url?scp=80052406524&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80052406524&partnerID=8YFLogxK
U2 - 10.1016/j.vaccine.2011.07.023
DO - 10.1016/j.vaccine.2011.07.023
M3 - Review article
C2 - 21781997
AN - SCOPUS:80052406524
SN - 0264-410X
VL - 29
SP - 7242
EP - 7250
JO - Vaccine
JF - Vaccine
IS - 42
ER -